As noted by the folks at SentimenTrader, the Nasdaq Biotechnology Index has already risen 11% so far this year-- a strong move, especially in light of 32% and 66% gains in 2012 and 2013, respectively.
As sustainability comes into question, we thought we would take a quick look at the companies in the MSCI World biotech sub-industry that qualify as knowledge leaders.
The lone Asia Pacific biotechnology company began a correction early last year but has not (yet?) violated important support:
European biotech companies do not seem too far from support just yet:
However, quite a few of the North American companies look extended:
The picture presented in our point-and-figure charts is mirrored (for the most part) when we look at our intangible-adjusted valuation data with North American companies trading at a premium: